<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DESLORATADINE- desloratadine tablet, film coated </strong><br>Mylan Pharmaceuticals Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use <span class="Bold">DESLORATADINE TABLETS</span> safely and effectively.  See full prescribing information for <span class="Bold">DESLORATADINE TABLETS</span>.<br> <br><span class="Bold">DESLORATADINE tablets, for oral use</span><br>Initial U.S. Approval: 2001</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta"> </p>
<p class="Highlighta">Dosage and Administration (<a href="#ID_9b32f9cb-afea-41c2-8ae2-ff586ed20a20">2</a>)     04/2014 </p>
<p class="Highlighta">Contraindications (<a href="#ID_cb22d698-842f-4ca8-8aee-3955f54e8b69">4</a>)     04/2014 </p>
</div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta"><span class="Bold">Desloratadine tablets are an H<span class="Sub">1</span>-receptor antagonist indicated for:</span> </p>
<dl>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">Seasonal Allergic Rhinitis</span>:</span> relief of nasal and non-nasal symptoms in patients 12 years of age and older. (<a href="#ID_36c715c9-681d-4c3a-960d-3d24520a15e5">1.1</a>)</dd>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">Perennial Allergic Rhinitis</span>:</span> relief of nasal and non-nasal symptoms in patients 12 years of age and older. (<a href="#ID_92ff1970-02d7-40d9-aa78-d46b95754f9c">1.2</a>)</dd>
<dt>•</dt>
<dd>
<span class="Bold">Chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">Idiopathic Urticaria</span>: </span>symptomatic relief of <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, reduction in the number of <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, and size of <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span> in patients 12 years of age and older. (<a href="#ID_19fdb4b4-4962-421e-ad7d-ce799513f4ef">1.3</a>) </dd>
</dl>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta"><span class="Bold">Dosage (by age)<a href="#ID_9b32f9cb-afea-41c2-8ae2-ff586ed20a20">:</a></span> </p>
<p class="Highlighta"><span class="Bold">Adults and Adolescents 12 Years of Age and Over:</span> </p>
<dl>
<dt>•</dt>
<dd>Desloratadine tablets – one 5 mg tablet once daily </dd>
</dl>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Desloratadine tablets – 5 mg (<a href="#ID_362f3bbe-8fc6-4b6e-8178-77c6238a718b">3</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> (<a href="#ID_cb22d698-842f-4ca8-8aee-3955f54e8b69">4</a>, <a href="#ID_b683cde5-48d7-463f-91bc-79db80180aca">6.2</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> including <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> have been reported. In such cases, stop desloratadine at once and consider alternative treatments. (<a href="#ID_594fe81a-9c74-4dfa-8e73-1a106d602ecb">5.1</a>)</dd>
</dl></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<dl>
<dt>•</dt>
<dd>The most common adverse reactions (reported in ≥ 2% of adult and adolescent patients with <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span> and greater than placebo) were <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span>. (<a href="#ID_a79c9798-4e6e-4777-ba22-e1eac9178dc2">6.1</a>)</dd>
</dl>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact </span><span class="Bold">Mylan Pharmaceuticals Inc. at 1-877-446-3679 (1-877-4-INFO-RX)</span><span class="Bold"> or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</a></span> </p>
</div>
<div>
<div><div></div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>: dosage adjustment is recommended (<a href="#ID_2fd2f253-eb0a-491f-930e-0f03777b7d39">2.5</a>, <a href="#ID_6f3c0d41-aabb-484a-a893-99e072b4c6df">8.6</a>, <a href="#ID_c0d5cc38-7ea1-47c4-acfa-56bd6722f645">12.3</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic impairment</span>: dosage adjustment is recommended (<a href="#ID_2fd2f253-eb0a-491f-930e-0f03777b7d39">2.5</a>, <a href="#ID_e4a3d119-7164-4e74-b289-c3b110bf0765">8.7</a>, <a href="#ID_c0d5cc38-7ea1-47c4-acfa-56bd6722f645">12.3</a>)</dd>
</dl></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
</div>
<div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 9/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE </a></h1>
<h2><a href="#section-1.1" class="toc">1.1	<span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">Seasonal Allergic Rhinitis</span>  </a></h2>
<h2><a href="#section-1.2" class="toc">1.2	<span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">Perennial Allergic Rhinitis</span>  </a></h2>
<h2><a href="#section-1.3" class="toc">1.3	Chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">Idiopathic Urticaria</span>  </a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION </a></h1>
<h2><a href="#section-2.1" class="toc">2.1	Adults and Adolescents 12 Years of Age and Over  </a></h2>
<h2><a href="#section-2.2" class="toc">2.5	Adults with Hepatic or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>  </a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS </a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS </a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS </a></h1>
<h2><a href="#section-5.1" class="toc">5.1	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>  </a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS </a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Clinical Trials Experience  </a></h2>
<h2><a href="#section-6.2" class="toc">6.2	Post-Marketing Experience  </a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS </a></h1>
<h2><a href="#section-7.1" class="toc">7.1	Inhibitors of Cytochrome P450 3A4  </a></h2>
<h2><a href="#section-7.2" class="toc">7.2	Fluoxetine  </a></h2>
<h2><a href="#section-7.3" class="toc">7.3	Cimetidine  </a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS </a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy </a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers </a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use </a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use </a></h2>
<h2><a href="#section-8.5" class="toc">8.6	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>  </a></h2>
<h2><a href="#section-8.6" class="toc">8.7	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>  </a></h2>
<h1><a href="#section-9" class="toc">9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span> </a></h1>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE </a></h1>
<h1><a href="#section-11" class="toc">11 DESCRIPTION </a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY </a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of Action </a></h2>
<h2><a href="#section-12.2" class="toc">12.2 Pharmacodynamics </a></h2>
<h2><a href="#section-12.3" class="toc">12.3 Pharmacokinetics </a></h2>
<h1><a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY </a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </a></h2>
<h2><a href="#section-13.2" class="toc">13.2 Animal Toxicology and/or Pharmacology </a></h2>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES </a></h1>
<h2><a href="#section-14.1" class="toc">14.1	<span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">Seasonal Allergic Rhinitis</span>  </a></h2>
<h2><a href="#section-14.2" class="toc">14.2	<span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">Perennial Allergic Rhinitis</span> </a></h2>
<h2><a href="#section-14.3" class="toc">14.3	Chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">Idiopathic Urticaria</span>  </a></h2>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING </a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION </a></h1>
<h2><a href="#section-16.1" class="toc">17.1	Information for Patients </a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_994a3de7-741e-483c-9884-fe1ce86a5bca"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_36c715c9-681d-4c3a-960d-3d24520a15e5"></a><a name="section-1.1"></a><p></p>
<h2>1.1	<span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">Seasonal Allergic Rhinitis</span>  </h2>
<p class="First">Desloratadine tablets are indicated for the relief of the nasal and non-nasal symptoms of <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> in patients 12 years of age and older. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_92ff1970-02d7-40d9-aa78-d46b95754f9c"></a><a name="section-1.2"></a><p></p>
<h2>1.2	<span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">Perennial Allergic Rhinitis</span>  </h2>
<p class="First">Desloratadine tablets are indicated for the relief of the nasal and non-nasal symptoms of <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span> in patients 12 years of age and older. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_19fdb4b4-4962-421e-ad7d-ce799513f4ef"></a><a name="section-1.3"></a><p></p>
<h2>1.3	Chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">Idiopathic Urticaria</span>  </h2>
<p class="First">Desloratadine tablets are indicated for the symptomatic relief of <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, reduction in the number of <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, and size of <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, in patients with chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">idiopathic urticaria</span> 12 years of age and older. </p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_9b32f9cb-afea-41c2-8ae2-ff586ed20a20"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION </h1>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Desloratadine tablets may be taken without regard to meals.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5cc94e25-1b62-4846-b884-c7d615076012"></a><a name="section-2.1"></a><p></p>
<h2>2.1	Adults and Adolescents 12 Years of Age and Over  </h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">The recommended dose of desloratadine tablets is one 5 mg tablet once daily.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2fd2f253-eb0a-491f-930e-0f03777b7d39"></a><a name="section-2.2"></a><p></p>
<h2>2.5	Adults with Hepatic or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>  </h2>
<p class="First">In adult patients with liver or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, a starting dose of one 5 mg tablet every other day is recommended based on pharmacokinetic data. Dosing recommendation for children with liver or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> cannot be made due to lack of data <span class="Italics">[see <a href="#ID_c0d5cc38-7ea1-47c4-acfa-56bd6722f645">Clinical Pharmacology (12.3)</a>]. </span></p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="ID_362f3bbe-8fc6-4b6e-8178-77c6238a718b"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS </h1>
<p class="First">Desloratadine tablets are red film-coated, round, unscored tablets debossed with <span class="Bold">M</span> on one side of the tablet and <span class="Bold">D17</span> on the other side, containing 5 mg of desloratadine. </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_cb22d698-842f-4ca8-8aee-3955f54e8b69"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS </h1>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Desloratadine tablets are contraindicated in patients who are hypersensitive to this medication or to any of its ingredients or to loratadine <span class="Italics">[see <a href="#ID_594fe81a-9c74-4dfa-8e73-1a106d602ecb">Warnings and Precautions (5.1)</a> and <a href="#ID_b683cde5-48d7-463f-91bc-79db80180aca">Adverse Reactions (6.2)</a>]</span>.</span><span class="Italics"></span></p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_ac62c2ae-1800-4ae9-8727-b53f93142200"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_594fe81a-9c74-4dfa-8e73-1a106d602ecb"></a><a name="section-5.1"></a><p></p>
<h2>5.1	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>  </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> including <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> have been reported after administration of desloratadine. If such a reaction occurs, therapy with desloratadine should be stopped and alternative treatment should be considered. <span class="Italics">[See <a href="#ID_b683cde5-48d7-463f-91bc-79db80180aca">Adverse Reactions (6.2)</a>.] </span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_30fd9ae0-8a8b-4b82-8410-391614d62089"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS </h1>
<p class="First">The following adverse reactions are discussed in greater detail in other sections of the label:</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>. <span class="Italics">[See <a href="#ID_594fe81a-9c74-4dfa-8e73-1a106d602ecb">Warnings and Precautions (5.1)</a>.] </span>
</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a79c9798-4e6e-4777-ba22-e1eac9178dc2"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Clinical Trials Experience  </h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_143c58e2-933b-4097-a2e5-d3f5e1695dc4"></a><a name="section-6.1.1"></a><p></p>
<h3>
<span class="Bold"><span class="Italics">Adults and Adolescents</span></span><span class="Bold"><span class="Italics"></span></span>
</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e3f65809-4992-409d-9f70-111f9eb9efc5"></a><a name="section-6.1.1.1"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">Allergic Rhinitis</span> </h4>
<p class="First">In multiple-dose placebo-controlled trials, 2,834 patients ages 12 years or older received desloratadine tablets at doses of 2.5 mg to 20 mg daily, of whom 1,655 patients received the recommended daily dose of 5 mg. In patients receiving 5 mg daily, the rate of adverse events was similar between desloratadine and placebo-treated patients. The percent of patients who withdrew prematurely due to adverse events was 2.4% in the desloratadine group and 2.6% in the placebo group. There were no serious adverse events in these trials in patients receiving desloratadine. All adverse events that were reported by greater than or equal to 2% of patients who received the recommended daily dose of desloratadine tablets (5 mg once daily), and that were more common with desloratadine tablets than placebo, are listed in Table 1. </p>
<table width="725.15pt">
<caption><span>Table 1: Incidence of Adverse Events Reported by ≥ 2% of Adult and Adolescent <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">Allergic Rhinitis</span> Patients Receiving Desloratadine Tablets</span></caption>
<col width="41%">
<col width="29%">
<col width="29%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Adverse Event</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Desloratadine Tablets</span></p>
<p><span class="Bold">5 mg</span></p>
<p><span class="Bold">(n = 1,655)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Placebo<br></span></p>
<p><span class="Bold">(n = 1,652)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></span></span></p></td>
<td class="Botrule Toprule" valign="top"></td>
<td class="Botrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">4.1%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></span></p></td>
<td class="Botrule Toprule" valign="top"></td>
<td class="Botrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2.1%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.8%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></span></p></td>
<td class="Botrule Toprule" valign="top"></td>
<td class="Botrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.9%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorder</span></span></span></p></td>
<td class="Botrule Toprule" valign="top"></td>
<td class="Botrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2.1%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.8%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">Reproductive System and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast Disorders</span></span></span></p></td>
<td class="Botrule Toprule" valign="top"></td>
<td class="Botrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">Dysmenorrhea</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2.1%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.6%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold"><span class="Italics">General Disorders and Administration Site Conditions</span></span></p></td>
<td class="Botrule Toprule" valign="top"></td>
<td class="Botrule Rrule Toprule" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2.1%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.2%</p></td>
</tr>
</tbody>
</table>
<p>The frequency and magnitude of laboratory and electrocardiographic abnormalities were similar in desloratadine and placebo-treated patients. </p>
<p>There were no differences in adverse events for subgroups of patients as defined by gender, age, or race. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a8a34924-2e04-4d50-819c-b967637daf0e"></a><a name="section-6.1.2"></a><p></p>
<h3>
<span class="Bold"><span class="Italics">Chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">Idiopathic Urticaria</span></span></span><span class="Bold"><span class="Italics"></span></span>
</h3>
<p class="First">In multiple-dose, placebo-controlled trials of chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">idiopathic urticaria</span>, 211 patients ages 12 years or older received desloratadine tablets and 205 received placebo. Adverse events that were reported by greater than or equal to 2% of patients who received desloratadine tablets and that were more common with desloratadine than placebo were (rates for desloratadine and placebo, respectively): <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (14%, 13%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (5%, 2%), <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (5%, 1%), <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (4%, 3%), <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span> (3%, 2%), <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span> (3%, 1%), and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> (3%, 1%).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2ced56bd-937d-4e14-98f2-d8ae87be63db"></a><a name="section-6.1.3"></a><p></p>
<h3>
<span class="Bold"><span class="Italics">Pediatrics</span></span><span class="Bold"><span class="Italics"></span></span>
</h3>
<p class="First">Two hundred and forty-six pediatric subjects 6 months to 11 years of age received desloratadine syrup for 15 days in three placebo-controlled clinical trials. Pediatric subjects aged 6 to 11 years received 2.5 mg once a day, subjects aged 1 to 5 years received 1.25 mg once a day, and subjects 6 to 11 months of age received 1 mg once a day. </p>
<p>In subjects 6 to 11 years of age, no individual adverse event was reported by 2% or more of the subjects. </p>
<p>In subjects 2 to 5 years of age, adverse events reported for desloratadine and placebo in at least 2% of subjects receiving desloratadine syrup and at a frequency greater than placebo were <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (5.5%, 5.4%), <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span> (3.6%, 0%) and <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span> (3.6%, 0%). </p>
<p>In subjects 12 months to 23 months of age, adverse events reported for the desloratadine product and placebo in at least 2% of subjects receiving desloratadine syrup and at a frequency greater than placebo were <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (16.9%, 12.9%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (15.4%, 11.3%), <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infections</span> (10.8%, 9.7%), <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span> (10.8%, 6.5%), appetite increased (3.1%, 1.6%), <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span> (3.1%, 0%), <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span> (3.1%, 0%), parasitic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (3.1%, 0%), <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span> (3.1%, 0%), <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> maculopapular (3.1%, 0%). </p>
<p>In subjects 6 months to 11 months of age, adverse events reported for desloratadine and placebo in at least 2% of subjects receiving desloratadine syrup and at a frequency greater than placebo were <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infections</span> (21.2%, 12.9%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (19.7%, 8.1%), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (12.1%, 1.6%), <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> (12.1%, 11.3%), <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span> (10.6%, 9.7%), <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (9.1%, 8.1%), <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span> (6.1%, 0%), <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> (6.1%, 1.6%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (6.1%, 3.2%), <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> (4.5%, 1.6%), <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span> (4.5%, 1.6%), <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> (4.5%, 0%), <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span> (4.5%, 3.2%), <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> (3%, 1.6%), and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (3%, 0%).</p>
<p>There were no clinically meaningful changes in any electrocardiographic parameter, including the QTc interval. Only one of the 246 pediatric subjects receiving desloratadine syrup in the clinical trials discontinued treatment because of an adverse event. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b683cde5-48d7-463f-91bc-79db80180aca"></a><a name="section-6.2"></a><p></p>
<h2>6.2	Post-Marketing Experience  </h2>
<p class="First">Because adverse events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following spontaneous adverse events have been reported during the marketing of desloratadine: <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, rare cases of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> (such as <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>), <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">psychomotor hyperactivity</span>, <span class="product-label-link" type="condition" conceptid="372604" conceptname="Movement disorder">movement disorders</span> (including <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, <span class="product-label-link" type="condition" conceptid="4297396" conceptname="Tic">tics</span>, and <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span>), <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, and elevated liver enzymes including bilirubin, and very rarely, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_b9cdeac6-c7f8-4f0c-b3ac-21ab3c850639"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e7053832-c6de-4fa0-872c-47b431fb3a12"></a><a name="section-7.1"></a><p></p>
<h2>7.1	Inhibitors of Cytochrome P450 3A4  </h2>
<p class="First">In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3-hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. <span class="Italics">[See <a href="#ID_c0d5cc38-7ea1-47c4-acfa-56bd6722f645">Clinical Pharmacology (12.3)</a>.] </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ac7c897b-08a3-403a-9b34-5a211d02299d"></a><a name="section-7.2"></a><p></p>
<h2>7.2	Fluoxetine  </h2>
<p class="First">In controlled clinical studies co-administration of desloratadine with fluoxetine, a selective serotonin reuptake inhibitor (SSRI), resulted in increased plasma concentrations of desloratadine and 3-hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. <span class="Italics">[See <a href="#ID_c0d5cc38-7ea1-47c4-acfa-56bd6722f645">Clinical Pharmacology (12.3)</a>.] </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f210c2c2-24aa-42fc-aacc-0110763b6773"></a><a name="section-7.3"></a><p></p>
<h2>7.3	Cimetidine  </h2>
<p class="First">In controlled clinical studies co-administration of desloratadine with cimetidine, a histamine H<span class="Sub">2</span>-receptor antagonist, resulted in increased plasma concentrations of desloratadine and 3-hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. <span class="Italics">[See <a href="#ID_c0d5cc38-7ea1-47c4-acfa-56bd6722f645">Clinical Pharmacology (12.3)</a>.]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ID_b4900481-4569-4a57-abb8-7d321037e407"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS </h1>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_4a200682-7482-4794-9cf4-ed11f53ae681"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_51cc1505-b48b-4afb-82ab-0c58e8fc2f51"></a><a name="section-8.1.1"></a><p></p>
<h3>
<span class="Bold"><span class="Italics">Teratogenic Effects. Pregnancy Category C</span></span><span class="Bold"><span class="Italics"></span></span>
</h3>
<p class="First">There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, desloratadine should be used during pregnancy only if clearly needed. </p>
<p>Desloratadine was not teratogenic in rats or rabbits at approximately 210 and 230 times, respectively, the area under the concentration-time curve (AUC) in humans at the recommended daily oral dose. An increase in pre-implantation loss and a decreased number of implantations and fetuses were noted, however, in a separate study in female rats at approximately 120 times the AUC in humans at the recommended daily oral dose. Reduced body weight and slow righting reflex were reported in pups at approximately 50 times or greater than the AUC in humans at the recommended daily oral dose. Desloratadine had no effect on pup development at approximately 7 times the AUC in humans at the recommended daily oral dose. The AUCs in comparison referred to the desloratadine exposure in rabbits and the sum of desloratadine and its metabolites exposures in rats, respectively. <span class="Italics">[See <a href="#ID_3935c7e4-6527-430a-9d05-ca5492692973">Nonclinical Toxicology (13.2)</a>.] </span></p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_ec9a9fce-0bdc-438e-adcc-0e19c8eaf5e1"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers </h2>
<p class="First">Desloratadine passes into breast milk; therefore, a decision should be made whether to discontinue nursing or to discontinue desloratadine, taking into account the benefit of the drug to the nursing mother and the possible risk to the child. </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_f56286e1-ef20-4691-a9b1-7c91e55a2800"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use </h2>
<p class="First">The recommended dose of desloratadine syrup in the pediatric population is based on cross-study comparison of the plasma concentration of desloratadine in adults and pediatric subjects. The safety of desloratadine syrup has been established in 246 pediatric subjects aged 6 months to 11 years in three placebo-controlled clinical studies. Since the course of seasonal and <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span> and chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">idiopathic urticaria</span> and the effects of desloratadine are sufficiently similar in the pediatric and adult populations, it allows extrapolation from the adult efficacy data to pediatric patients. The effectiveness of desloratadine syrup in these age groups is supported by evidence from adequate and well-controlled studies of desloratadine tablets in adults. The safety and effectiveness of desloratadine tablets or desloratadine syrup have not been demonstrated in pediatric patients less than 6 months of age. <span class="Italics">[See <a href="#ID_c0d5cc38-7ea1-47c4-acfa-56bd6722f645">Clinical Pharmacology (12.3)</a>.] </span></p>
<p>The desloratadine orally disintegrating 2.5 mg tablet has not been evaluated in pediatric patients. Bioequivalence of the desloratadine orally disintegrating tablet and the previously marketed orally disintegrating tablet was established in adults. In conjunction with the dose-finding studies in pediatrics described, the pharmacokinetic data for desloratadine orally disintegrating tablets supports the use of the 2.5 mg dose strength in pediatric patients 6 to 11 years of age. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_6190040d-024c-4ce3-b761-be0350f3dc4b"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use </h2>
<p class="First">Clinical studies of desloratadine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. <span class="Italics">[See <a href="#ID_c0d5cc38-7ea1-47c4-acfa-56bd6722f645">Clinical Pharmacology (12.3)</a>.] </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6f3c0d41-aabb-484a-a893-99e072b4c6df"></a><a name="section-8.5"></a><p></p>
<h2>8.6	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>  </h2>
<p class="First">Dosage adjustment for patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is recommended <span class="Italics">[see <a href="#ID_2fd2f253-eb0a-491f-930e-0f03777b7d39">Dosage and Administration (2.5)</a> and <a href="#ID_c0d5cc38-7ea1-47c4-acfa-56bd6722f645">Clinical Pharmacology (12.3)</a>]</span>.<span class="Italics"></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e4a3d119-7164-4e74-b289-c3b110bf0765"></a><a name="section-8.6"></a><p></p>
<h2>8.7	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>  </h2>
<p class="First">Dosage adjustment for patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> is recommended <span class="Italics">[see <a href="#ID_2fd2f253-eb0a-491f-930e-0f03777b7d39">Dosage and Administration (2.5)</a> and <a href="#ID_c0d5cc38-7ea1-47c4-acfa-56bd6722f645">Clinical Pharmacology (12.3)</a>]</span>.<span class="Italics"></span></p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="ID_8573e0b1-0864-49e0-ba66-c416514eee0e"></a><a name="section-9"></a><p></p>
<h1>9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span> </h1>
<p class="First">There is no information to indicate that abuse or dependency occurs with desloratadine tablets. </p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID_ac1069ac-5764-4d72-b44d-e3bae796f8fd"></a><a name="section-10"></a><p></p>
<h1>10 OVERDOSAGE </h1>
<p class="First">In the event of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, consider standard measures to remove any unabsorbed drug. Symptomatic and supportive treatment is recommended. Desloratadine and 3-hydroxydesloratadine are not eliminated by hemodialysis. </p>
<p>Information regarding acute overdosage is limited to experience from post-marketing adverse event reports and from clinical trials conducted during the development of the desloratadine product. In a dose-ranging trial, at doses of 10 mg and 20 mg/day <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> was reported. </p>
<p>In another study, no clinically relevant adverse events were reported in normal male and female volunteers who were given single daily doses of desloratadine 45 mg for 10 days <span class="Italics">[see <a href="#ID_2e365306-256d-4688-99bf-c4015610b87d">Clinical Pharmacology (12.2)</a>]</span>.<span class="Italics"></span></p>
<p>Lethality occurred in rats at oral doses of 250 mg/kg or greater (estimated desloratadine and desloratadine metabolite exposures were approximately 120 times the AUC in humans at the recommended daily oral dose). The oral median lethal dose in mice was 353 mg/kg (estimated desloratadine exposures were approximately 290 times the human daily oral dose on a mg/m<span class="Sup">2</span> basis). No <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> occurred at oral doses up to 250 mg/kg in monkeys (estimated desloratadine exposures were approximately 810 times the human daily oral dose on a mg/m<span class="Sup">2</span> basis). </p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_e13a3df7-30a0-4882-9917-9ae8ada94498"></a><a name="section-11"></a><p></p>
<h1>11 DESCRIPTION </h1>
<p class="First">Desloratadine tablets are red film-coated, round, unscored tablets debossed with <span class="Bold">M</span> on one side of the tablet and <span class="Bold">D17</span> on the other side containing 5 mg of desloratadine, an antihistamine, to be administered orally. Desloratadine tablets also contain the following excipients: colloidal silicon dioxide, FD&amp;C Red No. 40 Aluminum Lake, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, pregelatinized starch (corn), sodium lauryl sulfate, talc and titanium dioxide.</p>
<p>Desloratadine is a white to off-white powder that is slightly soluble in water, but very soluble in ethanol and propylene glycol. It has a molecular formula: C<span class="Sub">19</span>H<span class="Sub">19</span>ClN<span class="Sub">2</span> and a molecular weight of 310.8. The chemical name is 8-Chloro-6,11-dihydro-11-(4-piperdinylidene)-5<span class="Italics">H</span>-benzo[5,6]cyclohepta[1,2-<span class="Italics">b</span>]pyridine and has the following structure: </p>
<div class="Figure">
<a name="id-205023061"></a><img alt="Desloratadine Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=91ce2b02-8f8e-4929-a962-b8f88a40b70a&amp;name=image-01.jpg">
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_0f5f2442-2bfa-430e-b55f-e88ed366e642"></a><a name="section-12"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY </h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_bc664860-2379-4f53-b21c-676c737f8d19"></a><a name="section-12.1"></a><p></p>
<h2>12.1 Mechanism of Action </h2>
<p class="First">Desloratadine is a long-acting tricyclic histamine antagonist with selective H<span class="Sub">1</span>-receptor histamine antagonist activity. Receptor binding data indicates that at a concentration of 2 to 3 ng/mL (7 nanomolar), desloratadine shows significant interaction with the human histamine H<span class="Sub">1</span>-receptor. Desloratadine inhibited histamine release from human mast cells <span class="Italics">in vitro</span>. Results of a radiolabeled tissue distribution study in rats and a radioligand H<span class="Sub">1</span>-receptor binding study in guinea pigs showed that desloratadine did not readily cross the blood brain barrier. The clinical significance of this finding is unknown. </p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="ID_2e365306-256d-4688-99bf-c4015610b87d"></a><a name="section-12.2"></a><p></p>
<h2>12.2 Pharmacodynamics </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2e3997b1-365a-4857-98e1-af7c1eb74e16"></a><a name="section-12.2.1"></a><p></p>
<h3>
<span class="Bold"><span class="Italics">Wheal and Flare</span></span><span class="Bold"><span class="Italics"></span></span>
</h3>
<p class="First">Human histamine skin wheal studies following single and repeated 5 mg doses of desloratadine have shown that the drug exhibits an antihistaminic effect by 1 hour; this activity may persist for as long as 24 hours. There was no evidence of histamine-induced skin wheal <span class="product-label-link" type="condition" conceptid="4052861" conceptname="Tachyphylaxis">tachyphylaxis</span> within the desloratadine 5 mg group over the 28-day treatment period. The clinical relevance of histamine wheal skin testing is unknown. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_635f1851-0a1e-4035-a220-6fa85cf1a636"></a><a name="section-12.2.2"></a><p></p>
<h3>
<span class="Bold"><span class="Italics">Effects on QTc</span></span><span class="Bold"><span class="Italics"></span></span>
</h3>
<p class="First">Single daily doses of 45 mg were given to normal male and female volunteers for 10 days. All ECGs obtained in this study were manually read in a blinded fashion by a cardiologist. In desloratadine-treated subjects, there was an increase in mean heart rate of 9.2 bpm relative to placebo. The QT interval was corrected for heart rate (QTc) by both the Bazett and Fridericia methods. Using the QTc (Bazett) there was a mean increase of 8.1 msec in desloratadine-treated subjects relative to placebo. Using QTc (Fridericia) there was a mean increase of 0.4 msec in desloratadine-treated subjects relative to placebo. No clinically relevant adverse events were reported. </p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_c0d5cc38-7ea1-47c4-acfa-56bd6722f645"></a><a name="section-12.3"></a><p></p>
<h2>12.3 Pharmacokinetics </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1f33ea3e-01eb-4f09-8d84-f2eac4109ef4"></a><a name="section-12.3.1"></a><p></p>
<h3>
<span class="Bold"><span class="Italics">Absorption</span></span><span class="Bold"><span class="Italics"></span></span>
</h3>
<p class="First">Following oral administration of a desloratadine 5 mg tablet once daily for 10 days to normal healthy volunteers, the mean time to maximum plasma concentrations (T<span class="Sub">max</span>) occurred at approximately 3 hours post dose and mean steady state peak plasma concentrations (C<span class="Sub">max</span>) and AUC of 4 ng/mL and 56.9 ng•hr/mL were observed, respectively. Neither food nor grapefruit juice had an effect on the bioavailability (C<span class="Sub">max </span>and AUC) of desloratadine. </p>
<p>The pharmacokinetic profile of desloratadine syrup was evaluated in a three-way crossover study in 30 adult volunteers. A single dose of 10 mL of desloratadine syrup containing 5 mg of desloratadine was bioequivalent to a single dose of 5 mg desloratadine tablet. Food had no effect on the bioavailability (AUC and C<span class="Sub">max</span>) of desloratadine syrup. </p>
<p>The pharmacokinetic profile of desloratadine orally disintegrating tablets was evaluated in a three-way crossover study in 24 adult volunteers. A single desloratadine orally disintegrating tablet containing 5 mg of desloratadine was bioequivalent to a single 5 mg desloratadine orally disintegrating tablet (original formulation) for both desloratadine and 3-hydroxydesloratadine. Food and water had no effect on the bioavailability (AUC and C<span class="Sub">max</span>) of desloratadine orally disintegrating tablets. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_009cf7be-acde-48f1-b86a-4904e2d7c588"></a><a name="section-12.3.2"></a><p></p>
<h3>
<span class="Bold"><span class="Italics">Distribution</span></span><span class="Bold"><span class="Italics"></span></span>
</h3>
<p class="First">Desloratadine and 3-hydroxydesloratadine are approximately 82% to 87% and 85% to 89% bound to plasma proteins, respectively. Protein binding of desloratadine and 3-hydroxydesloratadine was unaltered in subjects with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ffd0021a-7a36-4c7b-8bfc-6712049ac7b9"></a><a name="section-12.3.3"></a><p></p>
<h3>
<span class="Bold"><span class="Italics">Metabolism</span></span><span class="Bold"><span class="Italics"></span></span>
</h3>
<p class="First">Desloratadine (a major metabolite of loratadine) is extensively metabolized to 3-hydroxydesloratadine, an active metabolite, which is subsequently glucuronidated. The enzyme(s) responsible for the formation of 3-hydroxydesloratadine have not been identified. Data from clinical trials indicate that a subset of the general population has a decreased ability to form 3-hydroxydesloratadine, and are poor metabolizers of desloratadine. In pharmacokinetic studies (n = 3,748), approximately 6% of subjects were poor metabolizers of desloratadine (defined as a subject with an AUC ratio of 3-hydroxydesloratadine to desloratadine less than 0.1, or a subject with a desloratadine half-life exceeding 50 hours). These pharmacokinetic studies included subjects between the ages of 2 and 70 years, including 977 subjects aged 2 to 5 years, 1,575 subjects aged 6 to 11 years, and 1,196 subjects aged 12 to 70 years. There was no difference in the prevalence of poor metabolizers across age groups. The frequency of poor metabolizers was higher in Blacks (17%, n = 988) as compared to Caucasians (2%, n = 1,462) and Hispanics (2%, n = 1,063). The median exposure (AUC) to desloratadine in the poor metabolizers was approximately 6-fold greater than in the subjects who are not poor metabolizers. Subjects who are poor metabolizers of desloratadine cannot be prospectively identified and will be exposed to higher levels of desloratadine following dosing with the recommended dose of desloratadine. In multidose clinical safety studies, where metabolizer status was identified, a total of 94 poor metabolizers and 123 normal metabolizers were enrolled and treated with desloratadine syrup for 15 to 35 days. In these studies, no overall differences in safety were observed between poor metabolizers and normal metabolizers. Although not seen in these studies, an increased risk of exposure-related adverse events in patients who are poor metabolizers cannot be ruled out. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4504e0db-97dc-4213-bb78-cb331f546703"></a><a name="section-12.3.4"></a><p></p>
<h3>
<span class="Bold"><span class="Italics">Elimination</span></span><span class="Bold"><span class="Italics"></span></span>
</h3>
<p class="First">The mean plasma elimination half-life of desloratadine was approximately 27 hours. C<span class="Sub">max</span> and AUC values increased in a dose proportional manner following single oral doses between 5 mg and 20 mg. The degree of accumulation after 14 days of dosing was consistent with the half-life and dosing frequency. A human <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> balance study documented a recovery of approximately 87% of the <span class="Sup">14</span>C-desloratadine dose, which was equally distributed in urine and feces as metabolic products. Analysis of plasma 3-hydroxydesloratadine showed similar T<span class="Sub">max</span> and half-life values compared to desloratadine. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_cf6494b4-2200-4eca-acbf-c5a124be742d"></a><a name="section-12.3.5"></a><p></p>
<h3>
<span class="Bold"><span class="Italics">Special Populations</span></span><span class="Bold"><span class="Italics"></span></span>
</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_78a6b916-b945-4835-ab7d-693f1bdc9d97"></a><a name="section-12.3.5.1"></a><p></p>
<h4>Geriatric Subjects </h4>
<p class="First">In older subjects (≥ 65 years old; n = 17) following multiple-dose administration of desloratadine tablets, the mean C<span class="Sub">max</span> and AUC values for desloratadine were 20% greater than in younger subjects (&lt; 65 years old). The oral total body clearance (CL/F) when normalized for body weight was similar between the two age groups. The mean plasma elimination half-life of desloratadine was 33.7 hr in subjects ≥ 65 years old. The pharmacokinetics for 3-hydroxydesloratadine appeared unchanged in older versus younger subjects. These age-related differences are unlikely to be clinically relevant and no dosage adjustment is recommended in elderly subjects. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1fa7ee84-666e-4719-b400-926537d7ab92"></a><a name="section-12.3.5.2"></a><p></p>
<h4>Pediatric Subjects </h4>
<p class="First">In subjects 6 to 11 years old, a single dose of 5 mL of desloratadine syrup containing 2.5 mg of desloratadine, resulted in desloratadine plasma concentrations similar to those achieved in adults administered a single 5 mg desloratadine tablet. In subjects 2 to 5 years old, a single dose of 2.5 mL of desloratadine syrup containing 1.25 mg of desloratadine, resulted in desloratadine plasma concentrations similar to those achieved in adults administered a single 5 mg desloratadine tablet. However, the C<span class="Sub">max</span> and AUC of the metabolite (3-hydroxydesloratadine) were 1.27 and 1.61 times higher for the 5 mg dose of syrup administered in adults compared to the C<span class="Sub">max</span> and AUC obtained in children 2 to 11 years of age receiving 1.25 mg to 2.5 mg of desloratadine syrup. </p>
<p>A single dose of either 2.5 mL or 1.25 mL of desloratadine syrup containing 1.25 mg or 0.625 mg, respectively, of desloratadine was administered to subjects 6 to 11 months of age and 12 to 23 months of age. The results of a population pharmacokinetic analysis indicated that a dose of 1 mg for subjects aged 6 to 11 months and 1.25 mg for subjects 12 to 23 months of age is required to obtain desloratadine plasma concentrations similar to those achieved in adults administered a single 5 mg dose of desloratadine syrup. </p>
<p>The desloratadine orally disintegrating 2.5 mg tablet has not been evaluated in pediatric patients. Bioequivalence of the desloratadine orally disintegrating tablet and the original desloratadine orally disintegrating tablets was established in adults. In conjunction with the dose-finding studies in pediatrics described, the pharmacokinetic data for desloratadine orally disintegrating tablets supports the use of the 2.5 mg dose strength in pediatric patients 6 to 11 years of age. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1aa59c0e-74cd-471a-9b43-0ec81fc0fd79"></a><a name="section-12.3.5.3"></a><p></p>
<h4>Renally Impaired </h4>
<p class="First">Desloratadine pharmacokinetics following a single dose of 7.5 mg were characterized in patients with mild (n = 7; creatinine clearance 51 to 69 mL/min/1.73 m<span class="Sup">2</span>), moderate (n = 6; creatinine clearance 34 to 43 mL/min/1.73 m<span class="Sup">2</span>), and severe (n = 6; creatinine clearance 5 to 29 mL/min/1.73 m<span class="Sup">2</span>) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or hemodialysis dependent (n = 6) patients. In patients with mild and moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, median C<span class="Sub">max</span> and AUC values increased by approximately 1.2- and 1.9-fold, respectively, relative to subjects with normal renal function. In patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or who were hemodialysis dependent, C<span class="Sub">max</span> and AUC values increased by approximately 1.7- and 2.5-fold, respectively. Minimal changes in 3-hydroxydesloratadine concentrations were observed. Desloratadine and 3-hydroxydesloratadine were poorly removed by hemodialysis. Plasma protein binding of desloratadine and 3-hydroxydesloratadine was unaltered by <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Dosage adjustment for patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is recommended <span class="Italics">[see <a href="#ID_2fd2f253-eb0a-491f-930e-0f03777b7d39">Dosage and Administration (2.5)</a>]</span>.<span class="Italics"></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_99472679-5776-4645-94ff-c82e685e7ee5"></a><a name="section-12.3.5.4"></a><p></p>
<h4>Hepatically Impaired </h4>
<p class="First">Desloratadine pharmacokinetics were characterized following a single oral dose in patients with mild (n = 4), moderate (n = 4), and severe (n = 4) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> as defined by the Child-Pugh classification of hepatic function and eight subjects with normal hepatic function. Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, regardless of severity, had approximately a 2.4-fold increase in AUC as compared with normal subjects. The apparent oral clearance of desloratadine in patients with mild, moderate, and severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> was 37%, 36%, and 28% of that in normal subjects, respectively. An increase in the mean elimination half-life of desloratadine in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> was observed. For 3-hydroxydesloratadine, the mean C<span class="Sub">max</span> and AUC values for patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> were not statistically significantly different from subjects with normal hepatic function. Dosage adjustment for patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> is recommended <span class="Italics">[see <a href="#ID_2fd2f253-eb0a-491f-930e-0f03777b7d39">Dosage and Administration (2.5)</a>]</span>.<span class="Italics"></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e319d389-43f8-47ad-83ee-55a6c768b0a5"></a><a name="section-12.3.5.5"></a><p></p>
<h4>Gender </h4>
<p class="First">Female subjects treated for 14 days with desloratadine tablets had 10% and 3% higher desloratadine C<span class="Sub">max</span> and AUC values, respectively, compared with male subjects. The 3-hydroxydesloratadine C<span class="Sub">max</span> and AUC values were also increased by 45% and 48%, respectively, in females compared with males. However, these apparent differences are not likely to be clinically relevant and therefore no dosage adjustment is recommended. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5f0138a4-6e63-4c58-96f8-d40315644d2a"></a><a name="section-12.3.5.6"></a><p></p>
<h4>Race </h4>
<p class="First">Following 14 days of treatment with desloratadine tablets, the C<span class="Sub">max</span> and AUC values for desloratadine were 18% and 32% higher, respectively, in Blacks compared with Caucasians. For 3-hydroxydesloratadine there was a corresponding 10% reduction in C<span class="Sub">max</span> and AUC values in Blacks compared to Caucasians. These differences are not likely to be clinically relevant and therefore no dose adjustment is recommended. </p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_169cbc61-2124-40ed-b47f-0a523186687c"></a><a name="section-12.3.6"></a><p></p>
<h3>
<span class="Bold"><span class="Italics">Drug Interactions</span></span><span class="Bold"><span class="Italics"></span></span>
</h3>
<p class="First">In two controlled crossover clinical pharmacology studies in healthy male (n = 12 in each study) and female (n = 12 in each study) volunteers, desloratadine 7.5 mg (1.5 times the daily dose) once daily was co-administered with erythromycin 500 mg every 8 hours or ketoconazole 200 mg every 12 hours for 10 days. In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of 5 mg has been co-administered with azithromycin 500 mg followed by 250 mg once daily for 4 days (n = 18) or with fluoxetine 20 mg once daily for 7 days after a 23-day pretreatment period with fluoxetine (n = 18) or with cimetidine 600 mg every 12 hours for 14 days (n = 18) under steady state conditions to normal healthy male and female volunteers. Although increased plasma concentrations (C<span class="Sub">max</span> and AUC<span class="Sub">0 to 24 hrs</span>) of desloratadine and 3-hydroxydesloratadine were observed (see Table 2), there were no clinically relevant changes in the safety profile of desloratadine, as assessed by electrocardiographic parameters (including the corrected QT interval), clinical laboratory tests, vital signs, and adverse events. </p>
<table width="801.4pt">
<caption><span>Table 2: Changes in Desloratadine and 3-Hydroxydesloratadine Pharmacokinetics in Healthy Male and Female Volunteers </span></caption>
<col width="28%">
<col width="17%">
<col width="19%">
<col width="18%">
<col width="18%">
<tbody class="Headless">
<tr class="First">
<td valign="top"></td>
<td align="center" colspan="2" valign="top"><p class="First"><span class="Bold"><span class="Underline">Desloratadine</span></span></p></td>
<td align="center" colspan="2" valign="top"><p class="First"><span class="Bold"><span class="Underline">3-Hydroxydesloratadine</span></span></p></td>
</tr>
<tr>
<td class="Botrule" valign="top"></td>
<td class="Botrule" align="center" valign="top"><p class="First"><span class="Bold">C<span class="Sub">max</span></span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First"><span class="Bold">AUC<span class="Sub">0 to 24 hrs</span></span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First"><span class="Bold">C<span class="Sub">max</span></span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First"><span class="Bold">AUC<span class="Sub">0 to 24 hrs</span></span></p></td>
</tr>
<tr>
<td valign="top">
<p class="First"><span class="Bold">Erythromycin</span></p>
<p>(500 mg Q8h)</p>
</td>
<td align="center" valign="middle"><p class="First">+ 24%</p></td>
<td align="center" valign="middle"><p class="First">+ 14%</p></td>
<td align="center" valign="middle"><p class="First">+ 43%</p></td>
<td align="center" valign="middle"><p class="First">+ 40%</p></td>
</tr>
<tr>
<td valign="top">
<p class="First"><span class="Bold">Ketoconazole</span></p>
<p>(200 mg Q12h)</p>
</td>
<td align="center" valign="middle"><p class="First">+ 45%</p></td>
<td align="center" valign="middle"><p class="First">+ 39%</p></td>
<td align="center" valign="middle"><p class="First">+ 43%</p></td>
<td align="center" valign="middle"><p class="First">+ 72%</p></td>
</tr>
<tr>
<td valign="top">
<p class="First"><span class="Bold">Azithromycin</span></p>
<p>(500 mg day 1, 250 mg QD x 4 days)</p>
</td>
<td align="center" valign="middle"><p class="First">+ 15%</p></td>
<td align="center" valign="middle"><p class="First">+ 5%</p></td>
<td align="center" valign="middle"><p class="First">+ 15%</p></td>
<td align="center" valign="middle"><p class="First">+ 4%</p></td>
</tr>
<tr>
<td valign="top">
<p class="First"><span class="Bold">Fluoxetine</span></p>
<p>(20 mg QD)</p>
</td>
<td align="center" valign="middle"><p class="First">+ 15%</p></td>
<td align="center" valign="middle"><p class="First">+ 0%</p></td>
<td align="center" valign="middle"><p class="First">+ 17%</p></td>
<td align="center" valign="middle"><p class="First">+ 13%</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top">
<p class="First"><span class="Bold">Cimetidine</span></p>
<p>(600 mg Q12h)</p>
</td>
<td class="Botrule" align="center" valign="middle"><p class="First">+ 12%</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">+ 19%</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">- 11%</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">- 3%</p></td>
</tr>
</tbody>
</table>
<p> </p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="ID_48c54dc4-3e3a-4c41-b898-dbea65065326"></a><a name="section-13"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY </h1>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_e46ff291-889b-4d76-9d03-2acff92684b1"></a><a name="section-13.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_aed34933-402c-4981-ac32-cfebf32bb746"></a><a name="section-13.1.1"></a><p></p>
<h3>
<span class="Bold"><span class="Italics">Carcinogenicity Studies</span></span><span class="Bold"><span class="Italics"></span></span>
</h3>
<p class="First">The carcinogenic potential of desloratadine was assessed using a loratadine study in rats and a desloratadine study in mice. In a 2-year study in rats, loratadine was administered in the diet at doses up to 25 mg/kg/day (estimated desloratadine and desloratadine metabolite exposures were approximately 30 times the AUC in humans at the recommended daily oral dose). A significantly higher incidence of hepatocellular tumors (combined <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> and carcinomas) was observed in males given 10 mg/kg/day of loratadine and in males and females given 25 mg/kg/day of loratadine. The estimated desloratadine and desloratadine metabolite exposures in rats given 10 mg/kg of loratadine were approximately 7 times the AUC in humans at the recommended daily oral dose. The clinical significance of these findings during long-term use of desloratadine is not known. </p>
<p>In a 2-year dietary study in mice, males and females given up to 16 mg/kg/day and 32 mg/kg/day desloratadine, respectively, did not show significant increases in the incidence of any tumors. The estimated desloratadine and desloratadine metabolite exposures in mice at these doses were 12 and 27 times, respectively, the AUC in humans at the recommended daily oral dose. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8bfa5874-0cf9-4583-b978-8975b2032cae"></a><a name="section-13.1.2"></a><p></p>
<h3>
<span class="Bold"><span class="Italics">Genotoxicity Studies</span></span><span class="Bold"><span class="Italics"></span></span>
</h3>
<p class="First">In genotoxicity studies with desloratadine, there was no evidence of genotoxic potential in a reverse mutation assay (<span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span></span>/<span class="Italics">E. coli </span>mammalian microsome bacterial mutagenicity assay) or in two assays for chromosomal aberrations (human peripheral blood lymphocyte clastogenicity assay and mouse bone marrow micronucleus assay). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4cece564-d954-418a-8337-8b755f9762b6"></a><a name="section-13.1.3"></a><p></p>
<h3>
<span class="Bold"><span class="Italics">Impairment of Fertility</span></span><span class="Bold"><span class="Italics"></span></span>
</h3>
<p class="First">There was no effect on female fertility in rats at desloratadine doses up to 24 mg/kg/day (estimated desloratadine and desloratadine metabolite exposures were approximately 130 times the AUC in humans at the recommended daily oral dose). A male specific decrease in fertility, demonstrated by reduced female conception rates, decreased sperm numbers and motility, and histopathologic testicular changes, occurred at an oral desloratadine dose of 12 mg/kg in rats (estimated desloratadine and desloratadine metabolite exposures were approximately 45 times the AUC in humans at the recommended daily oral dose). Desloratadine had no effect on fertility in rats at an oral dose of 3 mg/kg/day (estimated desloratadine and desloratadine metabolite exposures were approximately 8 times the AUC in humans at the recommended daily oral dose). </p>
</div>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="ID_3935c7e4-6527-430a-9d05-ca5492692973"></a><a name="section-13.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_823f61dc-75b6-4745-a38a-d67111cc436e"></a><a name="section-13.2.1"></a><p></p>
<h3>
<span class="Bold"><span class="Italics">Reproductive Toxicology Studies</span></span><span class="Bold"><span class="Italics"></span></span>
</h3>
<p class="First">Desloratadine was not teratogenic in rats at doses up to 48 mg/kg/day (estimated desloratadine and desloratadine metabolite exposures were approximately 210 times the AUC in humans at the recommended daily oral dose) or in rabbits at doses up to 60 mg/kg/day (estimated desloratadine exposures were approximately 230 times the AUC in humans at the recommended daily oral dose). In a separate study, an increase in pre-implantation loss and a decreased number of implantations and fetuses were noted in female rats at 24 mg/kg (estimated desloratadine and desloratadine metabolite exposures were approximately 120 times the AUC in humans at the recommended daily oral dose). Reduced body weight and slow righting reflex were reported in pups at doses of 9 mg/kg/day or greater (estimated desloratadine and desloratadine metabolite exposures were approximately 50 times or greater than the AUC in humans at the recommended daily oral dose). Desloratadine had no effect on pup development at an oral dose of 3 mg/kg/day (estimated desloratadine and desloratadine metabolite exposures were approximately 7 times the AUC in humans at the recommended daily oral dose). </p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID_dad76a51-d015-4fa6-a203-8c28525ab726"></a><a name="section-14"></a><p></p>
<h1>14 CLINICAL STUDIES </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_406641c5-1862-418e-abb8-fa8f465f8429"></a><a name="section-14.1"></a><p></p>
<h2>14.1	<span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">Seasonal Allergic Rhinitis</span>  </h2>
<p class="First">The clinical efficacy and safety of desloratadine tablets were evaluated in over 2,300 patients 12 to 75 years of age with <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span>. A total of 1,838 patients received 2.5 to 20 mg/day of desloratadine in four double-blind, randomized, placebo-controlled clinical trials of 2 to 4 weeks’ duration conducted in the United States. The results of these studies demonstrated the efficacy and safety of desloratadine 5 mg in the treatment of adult and adolescent patients with <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span>. In a dose-ranging trial, desloratadine 2.5 to 20 mg/day was studied. Doses of 5, 7.5, 10, and 20 mg/day were superior to placebo; and no additional benefit was seen at doses above 5 mg. In the same study, an increase in the incidence of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> was observed at doses of 10 mg/day and 20 mg/day (5.2% and 7.6%, respectively), compared to placebo (2.3%). </p>
<p>In two 4-week studies of 924 patients (aged 15 to 75 years) with <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> and concomitant <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, desloratadine tablets 5 mg once daily improved <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> symptoms, with no decrease in pulmonary function. This supports the safety of administering desloratadine tablets to adult patients with <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> with mild to moderate <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. </p>
<p>Desloratadine tablets 5 mg once daily significantly reduced the Total Symptom Score (the sum of individual scores of nasal and non-nasal symptoms) in patients with <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span>. See Table 3. </p>
<table width="100%">
<caption><span>Table 3: TOTAL SYMPTOM SCORE (TSS) Changes in a 2-Week Clinical Trial in Patients with <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">Seasonal Allergic Rhinitis</span> </span></caption>
<col width="27%">
<col width="24%">
<col width="24%">
<col width="25%">
<tfoot>
<tr class="First Last"><td class="Botrule" align="left" colspan="4" valign="top">SEM = Standard Error of the Mean</td></tr>
<tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>At baseline, a total nasal symptom score (sum of four individual symptoms) of at least 6 and a total non-nasal symptom score (sum of four individual symptoms) of at least 5 (each symptom scored 0 to 3 where 0 = no symptom and 3 = severe symptoms) was required for trial eligibility. TSS ranges from 0 = no symptoms to 24 = maximal symptoms.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Mean reduction in TSS averaged over the 2-week treatment period.</dd>
</dl></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Treatment Group</span></p>
<p><span class="Bold">(n)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Mean Baseline</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p>
<p><span class="Bold">(SEM)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Change from Baseline</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a></p>
<p><span class="Bold">(SEM)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Placebo</span></p>
<p><span class="Bold">Comparison</span></p>
<p><span class="Bold">(<span class="Italics">P</span>-value)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Desloratadine</span></p>
<p>5 mg (171)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">14.2 (0.3)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">-4.3 (0.3)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Italics">P</span> &lt; 0.01</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Placebo</span> (173)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">13.7 (0.3)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">-2.5 (0.3)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
</tbody>
</table>
<p>There were no significant differences in the effectiveness of desloratadine tablets 5 mg across subgroups of patients defined by gender, age, or race.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4fe5aa62-edb9-4c7b-a623-8dc0e50a2756"></a><a name="section-14.2"></a><p></p>
<h2>14.2	<span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">Perennial Allergic Rhinitis</span> </h2>
<p class="First">The clinical efficacy and safety of desloratadine tablets 5 mg were evaluated in over 1,300 patients 12 to 80 years of age with <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span>. A total of 685 patients received 5 mg/day of desloratadine in two double-blind, randomized, placebo-controlled clinical trials of 4 weeks’ duration conducted in the United States and internationally. In one of these studies desloratadine tablets 5 mg once daily was shown to significantly reduce the Total Symptom Score in patients with <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span> (Table 4).</p>
<table width="100%">
<caption><span>Table 4: TOTAL SYMPTOM SCORE (TSS) Changes in a 4-Week Clinical Trial in Patients with <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">Perennial Allergic Rhinitis</span> </span></caption>
<col width="27%">
<col width="24%">
<col width="24%">
<col width="25%">
<tfoot>
<tr class="First Last"><td class="Botrule" align="left" colspan="4" valign="top">SEM = Standard Error of the Mean </td></tr>
<tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>At baseline, average of total symptom score (sum of five individual nasal symptoms and three non-nasal symptoms, each symptom scored 0 to 3 where 0 = no symptom and 3 = severe symptoms) of at least 10 was required for trial eligibility. TSS ranges from 0 = no symptoms to 24 = maximal symptoms.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">†</a></dt>
<dd>Mean reduction in TSS averaged over the 4-week treatment period.</dd>
</dl></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Treatment Group</span></p>
<p><span class="Bold">(n)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Mean Baseline</span><a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a></p>
<p><span class="Bold">(SEM)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Change from Baseline</span><a name="footnote-reference-4" href="#footnote-4" class="Sup">†</a></p>
<p><span class="Bold">(SEM)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Placebo</span></p>
<p><span class="Bold">Comparison</span></p>
<p><span class="Bold">(<span class="Italics">P</span>-value)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Desloratadine</span></p>
<p>5 mg (337)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">12.37 (0.18)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">-4.06 (0.21)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Italics">P</span> = 0.01</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Placebo</span> (337)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">12.30 (0.18)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">-3.27 (0.21)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
</tbody>
</table>
<p>  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_9da01db7-4e54-444b-96e4-a030a31eb4e3"></a><a name="section-14.3"></a><p></p>
<h2>14.3	Chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">Idiopathic Urticaria</span>  </h2>
<p class="First">The efficacy and safety of desloratadine tablets 5 mg once daily was studied in 416 chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">idiopathic urticaria</span> patients 12 to 84 years of age, of whom 211 received deslotaradine. In two double-blind, placebo-controlled, randomized clinical trials of 6 weeks duration, at the pre-specified 1 week primary time point evaluation, desloratadine tablets significantly reduced the severity of <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> when compared to placebo (Table 5). Secondary endpoints were also evaluated, and during the first week of therapy desloratadine tablets 5 mg reduced the secondary endpoints, “Number of Hives? and the “Size of the Largest Hive,? when compared to placebo. </p>
<table width="728.6pt">
<caption><span>Table 5: <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">PRURITUS</span> SYMPTOM SCORE Changes in the First Week of a Clinical Trial in Patients with Chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">Idiopathic Urticaria</span> </span></caption>
<col width="26%">
<col width="25%">
<col width="25%">
<col width="25%">
<tfoot>
<tr class="First Last"><td class="Botrule" align="left" colspan="4" valign="top"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span> scored 0 to 3 where 0 = no symptom to 3 = maximal symptom<br>SEM = Standard Error of the Mean</td></tr>
<tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>Mean reduction in <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> averaged over the first week of treatment.</dd>
</dl></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First Toprule">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Treatment Group</span></p>
<p><span class="Bold">(n)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Mean Baseline (SEM)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Change from Baseline</span><a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a><span class="Bold"><br>(SEM)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Placebo Comparison <br>(<span class="Italics">P-</span>value)</span></p></td>
</tr>
<tr class="Toprule">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Desloratadine</span><br>5 mg (115)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">2.19 (0.04)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">-1.05 (0.07)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Italics">P</span> &lt; 0.01</p></td>
</tr>
<tr class="Last Toprule">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Placebo <br></span>(110)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">2.21 (0.04)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">-0.52 (0.07)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="bottom"></td>
</tr>
</tbody>
</table>
<p></p>
<p>The clinical safety of desloratadine syrup was documented in three, 15-day, double-blind, placebo-controlled safety studies in pediatric subjects with a documented history of <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span>, chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">idiopathic urticaria</span>, or subjects who were candidates for antihistamine therapy. In the first study, 2.5 mg of desloratadine syrup was administered to 60 pediatric subjects 6 to 11 years of age. The second study evaluated 1.25 mg of desloratadine syrup administered to 55 pediatric subjects 2 to 5 years of age. In the third study, 1.25 mg of desloratadine syrup was administered to 65 pediatric subjects 12 to 23 months of age and 1 mg of desloratadine syrup was administered to 66 pediatric subjects 6 to 11 months of age. The results of these studies demonstrated the safety of desloratadine syrup in pediatric subjects 6 months to 11 years of age. </p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_1db98ee4-742d-4987-bb5e-be1ccd5ccd94"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING </h1>
<p class="First">Desloratadine Tablets are available containing 5 mg of desloratadine.</p>
<p>The 5 mg tablets are red film-coated, round, unscored tablets debossed with <span class="Bold">M </span>on one side of the tablet and <span class="Bold">D17</span> on the other side. They are available as follows:</p>
<p>NDC 0378-4017-01<br>bottles of 100 tablets</p>
<p>NDC 0378-4017-05<br>bottles of 500 tablets</p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]</span></p>
<p><span class="Bold">Heat sensitive. Avoid exposure at or above 30ºC (86ºF).</span></p>
<p><span class="Bold">Protect from moisture.</span></p>
<p>Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.</p>
<p><span class="Bold">PHARMACIST: </span>Dispense a Patient Information Leaflet with each prescription. </p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_232e2da4-a28d-4765-8fe8-8da3a8b4e993"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION </h1>
<p class="First">See FDA-Approved Patient Labeling (<a href="#ID_fabdb94b-dd53-4895-a8b3-d5d0320147d0">Patient Information</a>).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a13783d7-efeb-4751-9239-6151d2be1fd6"></a><a name="section-16.1"></a><p></p>
<h2>17.1	Information for Patients </h2>
<dl>
<dt>•</dt>
<dd>Patients should be instructed to use desloratadine tablets as directed.</dd>
<dt>•</dt>
<dd>As there are no food effects on bioavailability, patients can be instructed that desloratadine tablets may be taken without regard to meals.</dd>
<dt>•</dt>
<dd>Patients should be advised not to increase the dose or dosing frequency as studies have not demonstrated increased effectiveness at higher doses and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> may occur.</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="ID_fabdb94b-dd53-4895-a8b3-d5d0320147d0"></a><a name="section-17"></a><p></p>
<h1>PATIENT INFORMATION LEAFLET </h1>
<p class="First"><span class="Bold">DESLORATADINE TABLETS</span></p>
<p><span class="Bold">(des′′ lor a′ ta deen)</span></p>
<p><span class="Bold">5 mg</span></p>
<p>Read the Patient Information Leaflet that comes with desloratadine tablets before you start taking it and each time you get a refill. There may be new information. This leaflet is a summary of the information for patients. Your doctor or pharmacist can give you additional information. This leaflet does not take the place of talking to your doctor about your medical condition or treatment. </p>
<p><span class="Bold">What are desloratadine tablets? </span></p>
<p>Desloratadine tablets are a prescription medicine that contains the medicine desloratadine (an antihistamine). </p>
<p>Desloratadine tablets are used to help control the symptoms of: </p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> (<span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>, stuffy nose, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">runny nose</span> and <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> of the nose) in people 12 years of age and older. </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span> (<span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>, stuffy nose, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">runny nose</span> and <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> of the nose) in people 12 years of age and older. </dd>
<dt>•</dt>
<dd>chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">idiopathic urticaria</span> (long-term <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>) and to reduce the number and size of <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span> in people 12 years of age and older.</dd>
</dl>
<p><span class="Bold">Who should not take desloratadine tablets? </span></p>
<p>Do not take desloratadine tablets if you: </p>
<dl>
<dt>•</dt>
<dd>are allergic to desloratadine or any of the ingredients in desloratadine tablets. See the end of this leaflet for a complete list of ingredients. </dd>
<dt>•</dt>
<dd>are allergic to loratadine (Alavert<span class="Sup">®*</span>, Claritin<span class="Sup">®*</span>). </dd>
</dl>
<p>Talk to your doctor before taking this medicine if you have any questions about whether or not to take this medicine. </p>
<p><span class="Bold">What should I tell my doctor before taking desloratadine tablets? </span></p>
<p>Before you take desloratadine tablets, tell your doctor if you: </p>
<dl>
<dt>•</dt>
<dd>have liver or kidney problems. </dd>
<dt>•</dt>
<dd>have any other medical conditions. </dd>
<dt>•</dt>
<dd>are pregnant or plan to become pregnant. It is not known if desloratadine will harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. </dd>
<dt>•</dt>
<dd>are breast-feeding or plan to breast-feed. Desloratadine <span class="Bold">can pass into your breast milk</span>. Talk to your doctor about the best way to feed your baby if you take desloratadine tablets. </dd>
</dl>
<p><span class="Bold">Tell your doctor about all the medicines you take, </span>including prescription and non-prescription medicines, vitamins and herbal supplements. Desloratadine tablets may affect the way other medicines work, and other medicines may affect how desloratadine tablets work. Especially tell your doctor if you take: </p>
<dl>
<dt>•</dt>
<dd>ketoconazole (Nizoral<span class="Sup">®*</span>) </dd>
<dt>•</dt>
<dd>erythromycin (Ery-tab<span class="Sup">®*</span>, Eryc<span class="Sup">®*</span>, PCE<span class="Sup">®*)</span>
</dd>
<dt>•</dt>
<dd>azithromycin (Zithromax<span class="Sup">®*</span>, Zmax<span class="Sup">®*</span>) </dd>
<dt>•</dt>
<dd>antihistamines </dd>
<dt>•</dt>
<dd>fluoxetine (Prozac<span class="Sup">®*</span>) </dd>
<dt>•</dt>
<dd>cimetidine (Tagamet<span class="Sup">®*</span>) </dd>
</dl>
<p>Know the medicines you take. Keep a list of your medicines and show it to your doctor and pharmacist when you get a new medicine. </p>
<p><span class="Bold">How should I take desloratadine tablets? </span></p>
<dl>
<dt>•</dt>
<dd>Take desloratadine tablets exactly as your doctor tells you to take it. </dd>
<dt>•</dt>
<dd>Do not change your dose of desloratadine tablets or take more often than prescribed.</dd>
<dt>•</dt>
<dd>Desloratadine tablets can be taken with or without food. </dd>
<dt>•</dt>
<dd>If you take too many desloratadine tablets, call your doctor or get medical attention right away. </dd>
</dl>
<p><span class="Bold">What are the possible side effects of desloratadine tablets? </span></p>
<p>Desloratadine tablets may cause serious side effects, including: </p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span>. Stop taking desloratadine tablets and call your doctor right away or get emergency help if you have any of these symptoms: <dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> </dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> </dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span> </dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your lips, tongue, face, and throat </dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or trouble breathing </dd>
</dl>
</dd>
</dl>
<p>The most common side effects of desloratadine tablets in adults and children 12 years of age and older with <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span> include: </p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> </dd>
<dt>•</dt>
<dd>menstrual <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> </dd>
</dl>
<p>Increased <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> or <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span> can happen if you take more desloratadine tablets than your doctor prescribed to you. </p>
<p>Tell your doctor if you have any side effect that bothers you or that does not go away. </p>
<p>These are not all of the possible side effects of desloratadine tablets. For more information, ask your doctor or pharmacist. </p>
<p><span class="Bold">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. </span></p>
<p><span class="Bold">How should I store desloratadine tablets? </span></p>
<dl>
<dt>•</dt>
<dd>Store <span class="Bold">desloratadine tablets </span>at 20° to 25°C (68° to 77°F). </dd>
<dt>•</dt>
<dd>
<span class="Bold">Desloratadine tablets </span>are sensitive to heat. Do not store above 30°C (86°F). </dd>
<dt>•</dt>
<dd>Protect <span class="Bold">desloratadine tablets </span>from moisture. </dd>
</dl>
<p>Keep <span class="Bold">desloratadine tablets </span>and all medicines out of the reach of children. </p>
<p><span class="Bold">General information about desloratadine tablets</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a patient information leaflet. Do not use desloratadine tablets for a condition for which it was not prescribed. Do not give desloratadine tablets to other people, even if they have the same condition you have. It may harm them. </p>
<p>This Patient Information leaflet summarizes the most important information about desloratadine tablets. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about desloratadine tablets that is written for health professionals. </p>
<p>For more information, call Mylan Pharmaceuticals Inc. at 1-877-446-3679 (1-877-4-INFO-RX).<span class="Bold"></span></p>
<p><span class="Bold">What are the ingredients in desloratadine tablets? </span></p>
<p><span class="Bold">Active ingredient:</span> desloratadine </p>
<p><span class="Bold">Inactive ingredients in desloratadine tablets: </span>colloidal silicon dioxide, FD&amp;C Red No. 40 Aluminum Lake, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, pregelatinized starch (corn), sodium lauryl sulfate, talc and titanium dioxide.</p>
<p>*The brands listed are registered trademarks of their respective owners.</p>
<p><span class="Bold">Mylan Pharmaceuticals Inc.<br></span>Morgantown, WV  26505  U.S.A.</p>
<p>REVISED SEPTEMBER 2015<br>DSLD:R5ppt</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_4f02b8e5-8f88-43cc-acbd-6d652ef7715a"></a><a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 5 mg  </h1>
<p class="First"><span class="Bold">NDC 0378-4017-01</span></p>
<p><span class="Bold">Desloratadine</span><br><span class="Bold">Tablets</span><br><span class="Bold">5 mg</span></p>
<p><span class="Bold">PHARMACIST: Dispense the accompanying</span><br><span class="Bold">Patient Information Leaflet to each patient.</span></p>
<p><span class="Bold">Rx only 100 TABLETS</span></p>
<p>Each film-coated tablet contains:<br>Desloratadine 5 mg</p>
<p>Dispense in a tight, light-resistant<br>container as defined in the USP<br>using a child-resistant closure.</p>
<p>Keep container tightly closed.</p>
<p><span class="Bold">Keep this and all medication</span><br><span class="Bold">out of the reach of children.</span></p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F).</span><br><span class="Bold">[See USP Controlled Room</span><br><span class="Bold">Temperature.]</span></p>
<p><span class="Bold">Heat sensitive. Avoid exposure</span><br><span class="Bold">at or above 30°C (86°F).</span></p>
<p><span class="Bold">Usual Dosage: </span>See accompanying<br>prescribing information.</p>
<p><span class="Bold">Mylan Pharmaceuticals Inc.</span><br>Morgantown, WV 26505 U.S.A.</p>
<p><span class="Bold">Mylan.com</span></p>
<p><span class="Bold">RM4017A1</span></p>
<div class="Figure">
<a name="id457457783"></a><img alt="Desloratadine Tablets 5 mg Bottle" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=91ce2b02-8f8e-4929-a962-b8f88a40b70a&amp;name=image-02.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DESLORATADINE 		
					</strong><br><span class="contentTableReg">desloratadine tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0378-4017</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DESLORATADINE</strong> (DESLORATADINE) </td>
<td class="formItem">DESLORATADINE</td>
<td class="formItem">5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">RED</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">M;D17</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0378-4017-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0378-4017-05</td>
<td class="formItem">500  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA078351</td>
<td class="formItem">07/02/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Mylan Pharmaceuticals Inc.
							(059295980)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 9/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>5a4dbb3a-fbd2-41a5-a3fa-ff346c5a3855</div>
<div>Set id: 91ce2b02-8f8e-4929-a962-b8f88a40b70a</div>
<div>Version: 5</div>
<div>Effective Time: 20150924</div>
</div>
</div> <div class="DistributorName">Mylan Pharmaceuticals Inc.</div></p>
</body></html>
